Terms: = Ovarian cancer AND FOXO3, FKHRL1, 2309, ENSG00000118689, MGC31925, MGC12739, FOXO2, FOXO3A, O43524, AF6q21, FKHRL1P2, DKFZp781A0677 AND Prognosis
10 results:
1. Screening and Identification of a Prognostic Model of ovarian cancer by Combination of Transcriptomic and Proteomic Data.
Jiang J; Chen Z; Wang H; Wang Y; Zheng J; Guo Y; Jiang Y; Mo Z
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189432
[TBL] [Abstract] [Full Text] [Related]
2. Pancancer analysis of SKA1 mutation and its association with the diagnosis and prognosis of human cancers.
Lan H; Yuan J; Zhang R; Jiang B; Li Q; Huang Z; Chen P; Xiang H; Zeng X; Xiao S
Genomics; 2023 Mar; 115(2):110554. PubMed ID: 36587749
[TBL] [Abstract] [Full Text] [Related]
3. foxo3a Reverses the Cisplatin Resistance in ovarian cancer.
Lu M; Chen X; Xiao J; Xiang J; Yang L; Chen D
Arch Med Res; 2018 Feb; 49(2):84-88. PubMed ID: 29716743
[TBL] [Abstract] [Full Text] [Related]
4. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and prognosis in ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract] [Full Text] [Related]
5. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
[TBL] [Abstract] [Full Text] [Related]
6. An Analysis of Prognostic Factors in Patients with ovarian Malignant Germ Cell Tumors Who Are Treated with Fertility-Preserving Surgery.
Yang ZJ; Liu ZC; Wei RJ; Li L
Gynecol Obstet Invest; 2016; 81(1):1-9. PubMed ID: 25967958
[TBL] [Abstract] [Full Text] [Related]
7. KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of foxo3a.
Huang L; Wang HY; Li JD; Wang JH; Zhou Y; Luo RZ; Yun JP; Zhang Y; Jia WH; Zheng M
Cell Death Dis; 2013 Aug; 4(8):e745. PubMed ID: 23907459
[TBL] [Abstract] [Full Text] [Related]
8. The expression and prognosis of foxo3a and Skp2 in human ovarian cancer.
Lu M; Zhao Y; Xu F; Wang Y; Xiang J; Chen D
Med Oncol; 2012 Dec; 29(5):3409-15. PubMed ID: 22714061
[TBL] [Abstract] [Full Text] [Related]
9. The expression and significance of pThr32-foxo3a in human ovarian cancer.
Lu M; Xiang J; Xu F; Wang Y; Yin Y; Chen D
Med Oncol; 2012 Jun; 29(2):1258-64. PubMed ID: 21452041
[TBL] [Abstract] [Full Text] [Related]
10. Low expression of foxo3a is associated with poor prognosis in ovarian cancer patients.
Fei M; Zhao Y; Wang Y; Lu M; Cheng C; Huang X; Zhang D; Lu J; He S; Shen A
Cancer Invest; 2009 Jan; 27(1):52-9. PubMed ID: 19160093
[TBL] [Abstract] [Full Text] [Related]
